Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134976 | 1.00 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL18867652 | 0.77 | — | — | |
| SCHEMBL14134882 | 0.76 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL26631944 | 0.76 | CA2 (0.34) | CA2CA12CA1CA9CHKA | |
| SCHEMBL14952087 | 0.75 | F2 (0.46) | CA2CA12CA1CA9PHGDH | |
| Hydrochloric Acid SCHEMBL538526 | 0.73 | CA2 (0.41) | CA2CA12CA1CA9CHKA | |
| SCHEMBL26631949 | 0.73 | NOS1 (0.39) | CA2CA12CA1CA9CHKA | |
| SCHEMBL12656550 | 0.71 | LMNA (0.59) | CA2CA12CA1CA9PHGDH | |
| SCHEMBL14134809 | 0.71 | CA2 (0.39) | CA2CA12CA1CA9CHKA | |
| SCHEMBL12151945 | 0.71 | KDM4E (0.35) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212445-A1 | POLYAMIDINE-CONTAINING MEMBRANES FOR CO2 SEPARATIONS FROM GASEOUS STREAMS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-11-02 | — | — | WO | claimed |
| US-20060122164-A1 | Carboxylic acid esters of pharmaceutical compounds | ASCHER GERD | 2006-06-08 | — | — | US | disclosed |
| CN-1745086-A | Carboxylic acid esters of pharmaceutical compounds | SANDOZ AG (CH) | 2006-03-08 | — | — | CN | disclosed |
| EP-1590354-A2 | CARBOXYLIC ACID ESTERS OF PHARMACEUTICAL COMPOUNDS | Sandoz AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-0965327-B1 | WRINKLING MODIFIERS | KAO CORP (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004067536-A2 | CARBOXYLIC ACID ESTERS TO IMPROVE BIOAVAILABILITY OF PHARMACEUTICAL COMPOUNDS | SANDOZ AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| US-6436920-B1 | AN ANTIWRINKLE AND ANTIAGING AGENT (COSMETIC SKIN CARE AGENT) COMPRISING A GUANIDINE DERIVATIVE | KAO CORPORATION (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020022611-A1 | Wrinkling modifiers | KAO CORPORATION (JP) | 2002-02-21 | — | — | US | disclosed |
| US-6306848-B1 | SKIN TREATMENT | KAO CORPORATION (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0965327-A1 | WRINKLING MODIFIERS | Kao Corporation (JP) | 1999-12-22 | — | — | EP | disclosed |
| EP-0719244-A1 | PROCESS OF PREPARING 2,3,5-TRIHALOBENZALDEHYDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007877-A1 | PROCESS OF PREPARING 2,3,5-TRIHALOBENZALDEHYDE | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122164-A1 | Carboxylic acid esters of pharmaceutical compounds | MCCC2, HCAR2, CA7 | CA2 19/4885CA12 61/4885CA1 126/4885 |
| US-20020022611-A1 | Wrinkling modifiers | AZI2, ARG1, CUTA | CA2 2783/4885CA12 4878/4885CA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.